QURE
uniQure·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 6
Bearish signal 2
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
Gap Down
Significant Net Income Decline
Revenue Beats Expectation
EPS Beats Expectation
RSI Oversold
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About QURE
Uniqure N.V.
A leading gene therapy company that develops innovative treatments for genetic diseases
Paasheuvelweg 25a, 1105 BP Amsterdam, The Netherlands
--
UniQure N.V. was established as a private limited liability company on January 9, 2012 in accordance with the relevant provisions of the Dutch law. The company is a biotechnology company specializing in gene therapy, dedicated to the development of a single treatment pathway for rare and critically ill patients. Its pipeline includes clinical drug candidates for Huntington's disease, amyotrophic lateral sclerosis associated with SOD 1 mutations, refractory median temporal lobe epilepsy and Fabry disease, reflecting the focus on advancing innovative therapies in the field of gene therapy.
Earnings Call
Q2/2025
Estimate EPS-0.882284
Actual EPS-0.69
Estimate Revenue5.76M
Actual Revenue5.30M
uniQure's Q2 2025: Navigating Contradictions in AMT-130 Strategy, Regulatory Path, and Market Expansion
Jul 29,2025 09:17
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
QURE has released its 2025 Q3 earnings. EPS was reported at -1.38, versus the expected -0.879928, missing expectations. The chart below visualizes how QURE has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
QURE has released its 2025 Q3 earnings report, with revenue of 3.70M, reflecting a YoY change of 61.83%, and net profit of -80.53M, showing a YoY change of -81.46%. The Sankey diagram below clearly presents QURE's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
